Stay updated with breaking news from ஆரோன் ஹட்டா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Repeat Offenders harvard.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from harvard.edu Daily Mail and Mail on Sunday newspapers.
Analysis shows how rare population of cancer cells contributes to disease relapse miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
E-Mail BOSTON - A gene called KRAS is one of the most commonly mutated genes in all human cancers, and targeted drugs that inhibit the protein expressed by mutated KRAS have shown promising results in clinical trials, with potential approvals by the U.S. Food and Drug Administration anticipated later this year. Unfortunately, cancer cells often develop additional mutations that make them resistant to such targeted drugs, resulting in disease relapse. Now researchers led by a team at Massachusetts General Hospital (MGH) have identified the first resistance mechanisms that may occur to these drugs and identified strategies to overcome them. The findings are published in ....
Share this article Share this article CAMBRIDGE, Mass., Jan. 27, 2021 /PRNewswire/ Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced a $50M Series A financing from Deerfield Management. The company also announced its launch of a portfolio of innovative small molecule kinase inhibitors with parallel lead programs in non-small cell lung cancer (NSCLC), including NUV-520 – a potential best-in-class ROS1-selective inhibitor - and NUV-655 – an ALK-selective inhibitor. These novel molecules have been designed through Nuvalent s proprietary discovery efforts to specifically solve for the dual challenges of kinase resistance and selectivity, with the goals of minimizing adverse events and driving more durable responses for patients with cancer. Chief Executive Officer James Porter, Ph.D., leads an experienced team with deep expertise in structure-based drug design, oncology drug devel ....